ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
about
Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future PerspectiveClinical Application of Targeted Next Generation Sequencing for Colorectal CancersQuality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial.Trifluridine/Tipiracil: A Review in Metastatic Colorectal Cancer.Patient considerations in metastatic colorectal cancer - role of panitumumab.Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal CancerMolecular classifications of gastric cancers: Novel insights and possible future applications.Predictive model for high-frequency microsatellite instability in colorectal cancer patients over 50 years of age.Multidisciplinary approach of colorectal cancer liver metastases.Diagnostic accuracy of magnetic resonance, computed tomography and contrast enhanced ultrasound in radiological multimodality assessment of peribiliary liver metastases.Making Meaningful Clinical Use of BiomarkersImproving Outcomes in Patients with CRC: The Role of Patient Reported Outcomes-An ESDO ReportDetection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal CancerPrimary and acquired resistance to biologic therapies in gastrointestinal cancers.A Complete Response Case in a Patient with Multiple Lung Metastases of Rectal Cancer Treated with Bevacizumab plus XELIRI Therapy.Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars.Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives.Recommendations for SIR-Spheres Y-90 resin microspheres in chemotherapy-refractory/intolerant colorectal liver metastases.The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.Genetic and epigenetic markers in colorectal cancer screening: recent advances.Future perspectives of circulating tumor DNA in colorectal cancer.Comprehensive Review on Colorectal Cancer and Transplant.High early growth response 1 (EGR1) expression correlates with resistance to anti-EGFR treatment in vitro and with poorer outcome in metastatic colorectal cancer patients treated with cetuximab.Immunotherapy for gastric cancers: emerging role and future perspectives.From tumour heterogeneity to advances in precision treatment of colorectal cancer.Current and future biomarkers in the treatment of colorectal cancer.The IR Evolution in Oncology: Tools, Treatments, and Guidelines.Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study.Overall Survival and Metastasis Resections in Patients with Metastatic Colorectal Cancer Using Electronic Medical Records.BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.Determinants of metastatic competency in colorectal cancer.Immunotherapy for colorectal cancer: where are we heading?Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.Colorectal cancer molecular profiling: from IHC to NGS in search of optimal algorithm.BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies.Yttrium-90 Radioembolization for Metastatic Colorectal Cancer: Outcomes by Number of Lines of Therapy.MicroRNAs as a tool to aid stratification of colorectal cancer patients and to guide therapy.The safety and effectiveness of robot-assisted versus laparoscopic TME in patients with rectal cancer: A meta-analysis and systematic review.
P2860
Q28070038-E2D6218C-7CE8-4EF4-A1D4-1D0F3B567623Q28077199-CCCC711F-1A64-46BA-812F-253AC879868BQ30313818-DB85ECEF-DA58-46C2-996A-D9D243191B92Q33434890-12178570-BB8B-42A1-A77F-4F79F0F6FC2AQ33563293-C2E00D1B-C0D0-437A-9804-0BB948ADE5A5Q33624491-856D751D-3C7E-47DB-929F-51E02BB1C0FAQ33696201-3FB04D9A-199D-4DB5-A554-C52D6F77D7DCQ33775336-2793A48F-A28F-4C85-ABF7-E051C88E215AQ33779859-168F8E6D-6739-4AEA-B737-5101B9613F26Q33817430-A613B49B-0866-483C-BF38-B22032F1A982Q33821481-71CD0E02-3A12-4276-BE37-F7F9B74B5476Q33832740-8DB9A676-F9C5-44A5-B0EB-BFBD81BDE111Q33889715-2913C14D-4FE4-4297-859C-760DD9F9F13CQ33895573-BDD1BF35-8DD9-485F-A678-82E03B110233Q37634877-7181A34C-12E5-46D8-B705-C531D4DEDC17Q38621699-86D5C2EF-623C-4FD5-B577-3E419C6C529EQ38643555-C20C5FE4-89B0-4496-BABD-2B4C04153101Q38650454-3D36F2B4-5308-490D-8373-0C39D7B7590DQ38658289-F56C5044-6464-424C-B2F3-D8724CC7E64AQ38668967-B70B897A-C095-4B31-A46B-EE9518F70736Q38676702-BB0CF5B2-48E9-4D48-96E6-3779CB2CF76AQ38685749-A1830156-FFC1-4FF7-856C-6888E3D1847EQ38687757-D098A229-8389-4EA2-AEF0-E3BE36AE4707Q38724794-2DF1B76D-5632-44F2-BBDA-FA162CD1FBBAQ38738652-F444A741-D6EA-4B80-9B92-A55C614889C6Q38786707-ADF8FF3D-B73F-473C-A5D1-4937A8455FF7Q38787244-323923F2-CF0D-49A5-BD4D-333DE372CC9DQ38792207-32D3DED2-2A02-4D50-B2B4-275038FDC1A8Q38805622-76EA501D-EDEA-4A9C-B194-81FECEE41B3CQ38947007-27738F59-C08C-45A4-95D1-2F67C9F88533Q38953687-3263AFCA-B178-48EE-A06A-4D5ED932F8D0Q39010073-D5596387-ED90-458E-8C50-4A427286AAEFQ39085740-8AF7DE35-078A-4E03-869F-23AA4721444FQ39218636-45EC65DE-43F2-4A81-9FED-094B336C6450Q39223563-CF226E56-204A-451E-9AE0-0D42ECDF90A6Q39334444-EDEEA04A-5789-475E-A3DF-D531EE48961CQ39347386-D2E64FE5-852F-4BAD-9EAC-EDFF97894DFFQ39349646-734EFAEE-3C8F-4377-987E-2626151944C8Q39390383-5A6B1D50-77DF-41AD-8024-FF6702054B63Q39445463-5A04AC57-CB9D-4599-8413-642D3F682102
P2860
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
ESMO consensus guidelines for ...... metastatic colorectal cancer.
@en
ESMO consensus guidelines for ...... metastatic colorectal cancer.
@nl
type
label
ESMO consensus guidelines for ...... metastatic colorectal cancer.
@en
ESMO consensus guidelines for ...... metastatic colorectal cancer.
@nl
prefLabel
ESMO consensus guidelines for ...... metastatic colorectal cancer.
@en
ESMO consensus guidelines for ...... metastatic colorectal cancer.
@nl
P2093
P50
P356
P1433
P1476
ESMO consensus guidelines for ...... h metastatic colorectal cancer
@en
P2093
A Cervantes
D Papamichael
P304
P356
10.1093/ANNONC/MDW235
P50
P577
2016-07-05T00:00:00Z